NEW YORK, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have
commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead
plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links
provided. There is no cost or obligation to you.
Arlo Technologies, Inc. (NYSE: ARLO)
Class Period: Investors who purchased shares pursuant and/or traceable to the Company's Registration Statement and
Prospectus issued in connection with the August 3, 2018 Initial Public Offering
Lead Plaintiff Deadline: March 25, 2019
Join the action: https://www.zlk.com/pslra-1/arlo-technologies-inc-loss-form?wire=3
The filed complaint alleges that the Registration Statement made materially false and/or misleading statements and/or failed to
disclose that: (i) there was a flaw and/or quality issue with Arlo’s newly designed battery for its Ultra camera systems; (ii) this
flaw and/or quality issue with the Ultra battery could result in a shipping delay of Arlo’s Ultra product; (iii) such a shipping
delay endangered Arlo’s chances of launching the Ultra product in time for the crucial holiday season; (iv) such a shipping delay
would allow Arlo’s competitors to capitalize on the Ultra product’s missed launch, thereby increasing their own market share; (v)
Arlo’s consumers had been experiencing battery drain issues and other battery-related issues in connection with recent firmware
updates; (vi) because of the foregoing, Arlo’s fourth quarter 2018 results and consumer base would be negatively impacted; and
(vii) as a result, Arlo’s Registration Statement was materially false and misleading at all relevant times.
To learn more about the Arlo Technologies, Inc. class action contact jlevi@levikorsinsky.com.
Dentsply Sirona, Inc. (NASDAQ: XRAY)
Class Period: (i) all persons who purchased the common stock of Dentsply Sirona, Inc. (NASDAQ: XRAY) between February 20,
2014 and August 7, 2018; (ii) all Dentsply International Inc. shareholders who held shares as of the record date of December 2,
2015 and were entitled to vote with respect to the Acquisition at the January 11, 2016 special meeting of Dentsply International
Inc. shareholders; and (iii) all persons who purchased or otherwise acquired the common stock of Dentsply International in exchange
for their shares of common stock of Sirona in connection with the Acquisition
Lead Plaintiff Deadline: February 19, 2019
Join the action: https://www.zlk.com/pslra-1/dentsply-sirona-inc-loss-form?wire=3
According to the complaint, during the Class Period, Defendants attributed the Company’s financial performance to the Company’s
“innovation,” “operational improvement efforts,” “new products,” and “continued investments in sales and marketing” and told
investors that these factors helped the Company succeed despite the “highly competitive” market for its products. In reality, the
Company’s financial results had been buoyed by an anticompetitive scheme among the Company’s three primary distributors that
suppressed competition in the dental supply market and artificially inflated the price of dental supplies sold by Dentsply.
Further, Defendants concealed that an exclusive distribution arrangement that Sirona had with one of its distributors, Patterson
Companies, Inc. (“Patterson”), required Patterson to regularly make large minimum purchases regardless of demand and, as a result,
by 2015, Patterson had been supplied with so much excess inventory that it could not be sold. This channel-stuffing rendered the
Company’s reported sales, financial results and guidance materially false and misleading. In addition, the Company
represented that it reported its financial statements, including its goodwill, in accordance with generally accepted accounting
principles, or GAAP. In fact, the Company’s reported goodwill was artificially inflated and not reported in accordance with GAAP
because it did not reflect the financial impact of the anticompetitive scheme.
To learn more about the Dentsply Sirona, Inc. class action contact jlevi@levikorsinsky.com.
AxoGen, Inc. (NASDAQ: AXGN)
Class Period: August 7, 2017 - December 18, 2018
Lead Plaintiff Deadline: March 11, 2019
Join the action: https://www.zlk.com/pslra-1/axogen-inc-loss-form?wire=3
About the lawsuit: AxoGen, Inc. allegedly made materially false and/or misleading statements during the class period and/or
failed to disclose that: (1) the Company aggressively increased prices to mask lower sales; (2) the Company’s pricing alienated
customers and threatened the Company’s future growth; (3) ambulatory surgery centers form a significant part of the market for the
Company’s products; (4) such centers were especially sensitive to price increases; (5) the Company was dependent on a small number
of surgeons whom the Company paid to generate sales; (6) the Company’s consignment model for inventory was reasonably likely to
lead to channel stuffing; (7) the Company offered purchase incentives to sales representatives to encourage channel stuffing; (8)
the Company’s sales representatives were encouraged to backdate revenue to artificially inflate metrics; (9) the Company lacked
adequate internal controls to prevent such channel stuffing and backdating of revenue; (10) the Company’s key operating metrics,
such as number of active accounts, were overstated; and (11) as a result of the foregoing, Defendants’ positive statements about
the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
To learn more about the AxoGen, Inc. class action contact jlevi@levikorsinsky.com.
Allergan plc (NYSE: AGN)
Class Period: February 24, 2017 - December 19, 2018
Lead Plaintiff Deadline: February 19, 2019
Join the action: https://www.zlk.com/pslra-1/allergan-plc-loss-form?wire=3
About the lawsuit: During the class period, Allergan plc allegedly made materially false and/or misleading statements and/or
failed to disclose that: (i) textured breast implants manufactured by Allergan were linked to ALCL; (ii) the foregoing link to
cancer, when revealed, would foreseeably force Allergan to recall those textured breast implants from the market; and (iii) as a
result, the Company’s public statements were materially false and misleading at all relevant times.
To learn more about the Allergan plc class action contact jlevi@levikorsinsky.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any
recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys
have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of
dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
